A review of denosumab for the treatment of osteoporosis

References

• EriksenEFNormal and pathological remodeling of human trabecular bone: three dimensional reconstruction of the remodeling sequence in normals and in metabolic bone diseaseEndocr Rev1986743794083536460
   PubMed Web of Science ®Google Scholar
• ParfittAMOsteonal and hemi-osteonal remodeling: the spatial and temporal framework for signal traffic in adult human boneJ Cell Biochem19945532732867962158
   PubMed Web of Science ®Google Scholar
• KarsentyGWagnerEFReaching a genetic and molecular understanding of skeletal developmentDev Cell20022438940611970890
   PubMed Web of Science ®Google Scholar
• SudaTTakahashiNUdagawaNJimiEGillespieMTMartinTJModulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand familiesEndocr Rev199920334535710368775
   PubMed Web of Science ®Google Scholar
• RobbinsJASchottAMGarneroPDelmasPDHansDMeunierPJRisk factors for hip fracture in women with high BMD: EPIDOS studyOsteoporos Int200516214915415185066
   PubMed Web of Science ®Google Scholar
• DufresneTEChmielewskiPAManhartMDJohnsonTDBorahBRisedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomographyCalcif Tissue Int200373542343212964065
   PubMed Web of Science ®Google Scholar
• GlothFM3rdGundbergCMHollisBWHaddadJGJrTobinJDVitamin D deficiency in homebound elderly personsJAMA199527421168316867474272
   PubMed Web of Science ®Google Scholar
• LipsPVitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implicationsEndocr Rev200122447750111493580
   PubMed Web of Science ®Google Scholar
• JohnellOKanisJAOdénAFracture risk following an osteoporotic fractureOsteoporos Int200415317517914691617
   PubMedGoogle Scholar
• GullbergBJohnellOKanisJAWorld-wide projections for hip fractureOsteoporos Int1997754074139425497
   PubMed Web of Science ®Google Scholar
• No authors listedEffects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPIJAMA199627617138913968892713
   PubMed Web of Science ®Google Scholar
• DelmasPDBjarnasonNHMitlakBHEffects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal womenN Engl J Med199733723164116479385122
   PubMed Web of Science ®Google Scholar
• McClungMRWasnichRDHoskingDJPrevention of postmenopausal bone loss: six-year results from the Early Postmenopausal Intervention Cohort StudyJ Clin Endocrinol Metab200489104879488515472179
   PubMed Web of Science ®Google Scholar
• DelmasPDTreatment of postmenopausal osteoporosisLancet200235993222018202612076571
   PubMed Web of Science ®Google Scholar
• WattsNBDiabDLLong-term use of bisphosphonates in osteoporosisJ Clin Endocrinol Metab20109541555156520173017
   PubMed Web of Science ®Google Scholar
• ReckerRRGallagherRMacCosbePEEffect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of womenMayo Clin Proc200580785686116007889
   PubMed Web of Science ®Google Scholar
• CaroJJIshakKJHuybrechtsKFRaggioGNaujoksCThe impact of compliance with osteoporosis therapy on fracture rates in actual practiceOsteoporos Int200415121003100815167989
   PubMed Web of Science ®Google Scholar
• PadhiDJangGStouchBFangLPosvarESingle-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibodyJ Bone Miner Res2011261192620593411
   PubMed Web of Science ®Google Scholar
• CostaAGBilezikianJPSclerostin: therapeutic horizons based upon its actionsCurr Osteoporos Rep2012101647222234741
   PubMed Web of Science ®Google Scholar
• TakahashiNYamanaHYoshikiSOsteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow culturesEndocrinology19881224137313823345718
   PubMed Web of Science ®Google Scholar
• UdagawaNTakahashiNAkatsuTThe bone marrow-derived stromal cell lines MC3T3-G2/PA6 and ST2 support osteoclast-like cell differentiation in cocultures with mouse spleen cellsEndocrinology19891254180518132676473
   PubMed Web of Science ®Google Scholar
• UdagawaNTakahashiNAkatsuTOrigin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cellsProc Natl Acad Sci U S A19908718726072642169622
   PubMed Web of Science ®Google Scholar
• SudaTTakahashiNMartinTJModulation of osteoclast differentiationEndocr Rev199213166801555533
   PubMed Web of Science ®Google Scholar
• AndersonDMMaraskovskyEBillingsleyWLA homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell functionNature199739066561751799367155
   PubMed Web of Science ®Google Scholar
• YasudaHShimaNNakagawaNOsteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKLProc Natl Acad Sci U S A1998957359736029520411
   PubMed Web of Science ®Google Scholar
• LaceyDLTimmsETanHLOsteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activationCell19989321651769568710
   PubMed Web of Science ®Google Scholar
• WongBRRhoJArronJTRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cellsJ Biol Chem19972724025190251949312132
   PubMed Web of Science ®Google Scholar
• KongYYYoshidaHSarosiIOPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesisNature199939767173153239950424
   PubMed Web of Science ®Google Scholar
• NakashimaTKobayashiYYamasakiSProtein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokinesBiochem Biophys Res Commun2000275376877510973797
   PubMed Web of Science ®Google Scholar
• SchlöndorffJLumLBlobelCPBiochemical and pharmacological criteria define two shedding activities for TRANCE/OPGL that are distinct from the tumor necrosis factor alpha convertaseJ Biol Chem200127618146651467411278735
   PubMed Web of Science ®Google Scholar
• MiyamotoTAraiFOhnedaOTakagiKAndersonDMSudaTAn adherent condition is required for formation of multinuclear osteoclasts in the presence of macrophage colony-stimulating factor and receptor activator of nuclear factor kappa B ligandBlood200096134335434311110710
   PubMed Web of Science ®Google Scholar
• HikitaAYanaIWakeyamaHNegative regulation of osteoclastogenesis by ectodomain shedding of receptor activator of NF-kappaB ligandJ Biol Chem200628148368463685517018528
   PubMed Web of Science ®Google Scholar
• BucayNSarosiIDunstanCRosteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcificationGenes Dev1998129126012689573043
   PubMed Web of Science ®Google Scholar
• SimonetWSLaceyDLDunstanCROsteoprotegerin: a novel secreted protein involved in the regulation of bone densityCell19978923093199108485
   PubMed Web of Science ®Google Scholar
• HofbauerLCKhoslaSDunstanCRLaceyDLSpelsbergTCRiggsBLEstrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cellsEndocrinology199914094367437010465311
   PubMed Web of Science ®Google Scholar
• LocklinRMKhoslaSTurnerRTRiggsBLMediators of the bipha-sic responses of bone to intermittent and continuously administered parathyroid hormoneJ Cell Biochem200389118019012682918
   PubMed Web of Science ®Google Scholar
• HofbauerLCGoriFRiggsBLStimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosisEndocrinology1999140104382438910499489
   PubMed Web of Science ®Google Scholar
• NakashimaTHayashiMFukunagaTEvidence for osteocyte regulation of bone homeostasis through RANKL expressionNat Med201117101231123421909105
   PubMed Web of Science ®Google Scholar
• DanksLTakayanagiHImmunology and boneJ Biochem20131541293923750028
   PubMed Web of Science ®Google Scholar
• TakayanagiHOsteoimmunology: shared mechanisms and crosstalk between the immune and bone systemsNat Rev Immunol20077429230417380158
   PubMed Web of Science ®Google Scholar
• KongYYFeigeUSarosiIActivated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligandNature1999402675930430910580503
   PubMed Web of Science ®Google Scholar
• BachmannMFWongBRJosienRSteinmanRMOxeniusAChoiYTRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activationJ Exp Med199918971025103110190893
   PubMed Web of Science ®Google Scholar
• DesantiGECowanJEBaikSDevelopmentally regulated availability of RANKL and CD40 ligand reveals distinct mechanisms of fetal and adult cross-talk in the thymus medullaJ Immunol2012189125519552623152561
   PubMed Web of Science ®Google Scholar
• MoschenARKaserAEnrichBThe RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone lossGut200554447948715753532
   PubMed Web of Science ®Google Scholar
• AshcroftAJCruickshankSMCroucherPIColonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerinImmunity200319684986114670302
   PubMed Web of Science ®Google Scholar
• StolinaMGuoJFaggioniRBrownHSenaldiGRegulatory effects of osteoprotegerin on cellular and humoral immune responsesClin Immunol2003109334735414697750
   PubMed Web of Science ®Google Scholar
• KostenuikPJNguyenHQMcCabeJDenosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKLJ Bone Miner Res200924218219519016581
   PubMed Web of Science ®Google Scholar
• KostenuikPJSmithSYJoletteJSchroederJPyrahIOminskyMSDecreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibodyBone201149215116121457806
   PubMed Web of Science ®Google Scholar
• BekkerPJHollowayDNakanishiAArrighiMLeesePTDunstanCRThe effect of a single dose of osteoprotegerin in postmenopausal womenJ Bone Miner Res200116234836011204435
   PubMed Web of Science ®Google Scholar
• McClungMRole of RANKL inhibition in osteoporosisArthritis Res Ther20079Suppl 1S3
   Google Scholar
• BekkerPJHollowayDLRasmussenASA single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal womenJ Bone Miner Res20041971059106615176987
   PubMed Web of Science ®Google Scholar
• KumagaiYHasunumaTPadhiDA randomized, double-blind, placebo-controlled, single-dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of denosumab administered subcutaneously to postmenopausal Japanese womenBone20114951101110721871589
   PubMed Web of Science ®Google Scholar
• NakamuraTMatsumotoTSugimotoTShirakiMDose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosisOsteoporos Int20122331131114021927920
   PubMed Web of Science ®Google Scholar
• McClungMRLewieckiEMCohenSBDenosumab in postmenopausal women with low bone mineral densityN Engl J Med2006354882183116495394
   PubMed Web of Science ®Google Scholar
• LewieckiEMMillerPDMcClungMRTwo-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMDJ Bone Miner Res200722121832184117708711
   PubMed Web of Science ®Google Scholar
• MillerPDBologneseMALewieckiEMEffect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trialBone200843222222918539106
   PubMed Web of Science ®Google Scholar
• CummingsSRSan MartinJMcClungMRDenosumab for prevention of fractures in postmenopausal women with osteoporosisN Engl J Med2009361875676519671655
   PubMed Web of Science ®Google Scholar
• McClungMRBoonenSTorringOEffect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosisJ Bone Miner Res201227121121821976367
   PubMed Web of Science ®Google Scholar
• PapapoulosSChapurlatRLibanatiCFive years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extensionJ Bone Miner Res201227369470122113951
   PubMed Web of Science ®Google Scholar
• McClungMRLewieckiEMGellerMLEffect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trialOsteoporos Int201324122723522776860
   PubMed Web of Science ®Google Scholar
• BoneHGBologneseMAYuenCKEffects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone massJ Clin Endocrinol Metab201196497298021289258
   PubMed Web of Science ®Google Scholar
• ReidIRMillerPDBrownJPEffects of denosumab on bone histomorphometry: the FREEDOM and STAND studiesJ Bone Miner Res201025102256226520533525
   PubMed Web of Science ®Google Scholar
• BrownJPDempsterDWDingBBone remodeling in postmenopausal women who discontinued denosumab treatment: off-treatment biopsy studyJ Bone Miner Res201126112737274421735475
   PubMed Web of Science ®Google Scholar
• JassalSKvon MuhlenDBarrett-ConnorEMeasures of renal function, BMD, bone loss, and osteoporotic fracture in older adults: the Rancho Bernardo studyJ Bone Miner Res200722220321017059370
   PubMed Web of Science ®Google Scholar
• IshaniAPaudelMTaylorBCRenal function and rate of hip bone loss in older men: the Osteoporotic Fractures in Men StudyOsteoporos Int200819111549155618392664
   PubMed Web of Science ®Google Scholar
• JamalSASwanVJBrownJPKidney function and rate of bone loss at the hip and spine: the Canadian Multicentre Osteoporosis StudyAm J Kidney Dis201055229129920042259
   PubMed Web of Science ®Google Scholar
• BlockGABoneHGFangLLeeEPadhiDA single-dose study of denosumab in patients with various degrees of renal impairmentJ Bone Miner Res20122771471147922461041
   PubMed Web of Science ®Google Scholar
• MillerPDA review of the efficacy and safety of denosumab in postmenopausal women with osteoporosisTher Adv Musculoskelet Dis20113627128222870485
   PubMedGoogle Scholar
• ToulisKAAnastasilakisADIncreased risk of serious infections in women with osteopenia or osteoporosis treated with denosumabOsteoporos Int201021111963196420012939
   PubMed Web of Science ®Google Scholar
• von KeyserlingkCHopkinsRAnastasilakisAClinical efficacy and safety of denosumab in postmenopausal women with low bone mineral density and osteoporosis: a meta-analysisSemin Arthritis Rheum201141217818621616520
   PubMed Web of Science ®Google Scholar
• WooSBHellsteinJWKalmarJRNarrative [corrected] review: bisphosphonates and osteonecrosis of the jawsAnn Intern Med20061441075376116702591
   PubMed Web of Science ®Google Scholar
• CapsoniFLonghiMWeinsteinRBisphosphonate-associated osteonecrosis of the jaw: the rheumatologist’s roleArthritis Res Ther20068521917049069
   PubMed Web of Science ®Google Scholar
• AllenMRIwataKPhippsRBurrDBAlterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronateBone200639487287916765660
   PubMed Web of Science ®Google Scholar
• MHRADenosumab 60 mg (Prolia▾): rare cases of atypical femoral fracture with long-term use. [webpage on the Internet]LondonMHRA2013 Available from: http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON239411Accessed March 31, 2014
   Google Scholar
• TsaiJNUihleinAVLeeHTeriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trialLancet20133829886505623683600
   PubMed Web of Science ®Google Scholar
• Collin-OsdobyPRotheLAndersonFNelsonMMaloneyWOsdobyPReceptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesisJ Biol Chem200127623206592067211274143
   PubMed Web of Science ®Google Scholar
• KiechlSWittmannJGiaccariABlockade of receptor activator of nuclear factor-kappaB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitusNat Med201319335836323396210
   PubMed Web of Science ®Google Scholar
• FreemantleNSatram-HoangSTangETFinal results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal womenOsteoporos Int201223131732621927922
   PubMed Web of Science ®Google Scholar
• FreemantleNCooperCDiez-PerezAResults of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysisOsteoporos Int201324120921722832638
   PubMed Web of Science ®Google Scholar
• HiligsmannMReginsterJYPotential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic womenBone2010471344020303422
   PubMed Web of Science ®Google Scholar
• HiligsmannMReginsterJYCost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in BelgiumPharmacoeconomics2011291089591121692551
   PubMed Web of Science ®Google Scholar
• ParthanAKruseMYurginNHuangJViswanathanHNTaylorDCost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the USAppl Health Econ Health Policy201311548549723868102
   PubMedGoogle Scholar
• ChauDBeckerDLCoombesMEIoannidisGAdachiJDGoereeRCost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in CanadaJ Med Econ201215Suppl 131423035625
   PubMedGoogle Scholar
• JönssonBStrömOEismanJACost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosisOsteoporos Int201122396798220936401
   PubMed Web of Science ®Google Scholar